10x Genomics has entered a multi-year collaboration with Dana-Farber Cancer Institute to analyze tumor samples from several hundred patients with major solid tumor types. Researchers will apply the Chromium Flex single cell assay and Xenium spatial platform to generate high-resolution molecular maps capturing cellular composition and spatial architecture. By correlating these profiles with clinical outcomes for therapies including antibody-drug conjugates, radioligand treatments, bispecific antibodies and immune checkpoint inhibitors, the study aims to identify biomarkers linked to treatment response, resistance and disease progression. Investigators plan to define actionable biomarker signatures and design a clinical reporting framework that integrates spatial and single cell insights into precision oncology decision support.

To translate research findings into clinical workflows, 10x Genomics will build a CLIA-certified laboratory in Pleasanton, California. This facility will support assay implementation, analytical validation and processing of clinical samples under regulated conditions. The CLIA lab is intended to enable future development of innovative diagnostic tests based on single cell and spatial biology, providing the infrastructure needed for analytical and clinical validation of assays that could power next-generation oncology diagnostics.

Beyond oncology, 10x Genomics announced a collaboration with Brigham & Women’s Hospital to profile peripheral blood from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis, alongside healthy controls. Using single cell profiling over routine clinical visits, the study will track immune cell signatures through disease flare, remission and therapeutic response. Concurrently, a partnership with the Cancer Research Institute will generate over 20,000 single cell and spatial profiles in a multi-phase AI-driven immuno-oncology program. The pilot phase will produce about 3,000 samples to train AI models, with subsequent expansion using the Chromium Flex assay to profile more than 500 million cells, aiming to map immune behaviors that inform future immunotherapy and vaccine development.